Antifibrotic Activity of Sorafenib in Experimental Hepatic Fibrosis: Refinement of Inhibitory Targets, Dosing, and Window of Efficacy In Vivo (Q39291844)
scientific article published on August 24, 2012
Language:
(P31) (Q13442814)
(P50) (Q7436651)
(P304) 257-264
(P407) (Q1860)
(P433) 1
(P478) 58
(P577) Friday, August 24, 2012
(P953) https://europepmc.org/articles/pmc3543488?pdf=render
https://europepmc.org/articles/PMC3543488
https://europepmc.org/articles/PMC3543488?pdf=render
https://doi.org/10.1007/s10620-012-2325-y
http://link.springer.com/content/pdf/10.1007/s10620-012-2325-y.pdf
http://link.springer.com/article/10.1007/s10620-012-2325-y/fulltext.html
http://link.springer.com/content/pdf/10.1007/s10620-012-2325-y
(P1433) (Q15716711)
(P1476) "Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo" (language: en)
"Antifibrotic Activity of Sorafenib in Experimental Hepatic Fibrosis: Refinement of Inhibitory Targets, Dosing, and Window of Efficacy In Vivo" (language: en)
(P2093) Feng Hong
Hsini Chou
Maria Isabel Fiel
(P2860) (Q30465168)
(Q37865859)
(Q28296761)
(Q27861075)
(Q37006004)
(Q28583234)
(Q28282767)
(Q29616456)
(Q38333252)
(Q29617585)
(Q34391388)
(Q33822590)
(Q28582231)
(Q34190381)
(Q40192837)
(Q39807542)
(Q43071662)
(Q44151756)
(Q43476790)
(Q28192437)
(Q37639678)
(Q37708639)
(Q28192519)
(Q36951930)
(Q28211504)
(Q28219222)
(Q37859163)
(Q28249416)
(Q36469303)
(Q37197324)
(Q24313579)
(Q28574534)
(Q35548073)
(Q37639681)
(Q34296539)
(Q46527407)
(Q28189315)
(Q54964114)
(Q35634421)
(Q45930594)
(Q34993168)
(Q38313494)
(Q36469920)
(Q34456713)
(Q36882253)
(Q69850266)
(Q67743331)
other details
description scientific article published on August 24, 2012

External Links